hims & hers glp-1 says it will offer weight-loss drugs, shares surge Hims & Hers expands weight

These are significant numbers

In January 2025, the FDA approved an oral form of Novo Nordisks Wegovy (semaglutide) to treat obesity

Many patients report a reduction in appetite and improved blood sugar control within this time frame, which can lead to gradual weight loss

For sublingual drops, eating immediately after dosing washes medication off the oral mucosa before absorption is complete

and long-acting GLP-1 RAs, including exenatide once-weekly, liraglutide, albiglutide, dulaglutide, and semaglutide, known for providing more consistent glycemic control 48,49

We do not take insurance but work to keep our costs reasonable